Private placement of american depositary shares and issuance of underlying shares under general mandate
Filed with HKEX · Stock code 9688 ·
Zai Lab's next earnings callZai Lab (HKEX:9688) Q3 2026 Earnings Call · Nov 5, 2026 at 8:00 AM ESTRegister
6ix is reading this filing.
View original source (HKEXnews)Zai Lab Ltd. on 6ix
Earlier from Zai Lab
- Charter of the nominating and corporate governance committee
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
- Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
- Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Later from Zai Lab
- Overseas regulatory announcement - form 8-K
- Inside information - update on first data from global phase 1B clinical trial
- Notice of audit committee action
Follow Zai Lab into a list and get an email when it puts out news.
Follow Zai Lab